{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:16:05Z","timestamp":1791141365304,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fond de Recherche pour l\u2019Industrie et l\u2019Agriculture"},{"DOI":"10.13039\/501100002661","name":"Fonds de la Recherche Scientifique \u2013 FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Chronic lymphocytic leukemia (CLL) is heterogeneous with respect to prognosis and clinical outcome. The mutational status of the immunoglobulin variable heavy chain region (IGHV) has been used to classify patients into 2 groups in terms of overall survival (OS) and clinical characteristics, but the labor-intensive nature and the cost of this time-consuming analysis has prompted investigations of surrogate markers.<\/jats:p>\n               <jats:p>Methods: We developed a standardized quantitative real-time reverse transcription-PCR (qPCR) method to measure zeta-chain (TCR)-associated protein kinase (ZAP70) mRNA in purified CD19+ cells. We evaluated this and other methods (flow cytometry analyses of ZAP70 and CD38 proteins and qPCR analysis of lipoprotein lipase mRNA) in a cohort of 108 patients (median follow-up, 82 months) to evaluate any associations with IGHV mutational status, OS, and treatment-free survival (TFS).<\/jats:p>\n               <jats:p>Results: The association between qPCR-measured ZAP70 and IGHV mutational status was statistically significant [\u03c72 (1) = 50.95; P &amp;lt;0.0001], and the value of Cramer\u2019s V statistic (0.72) indicated a very strong relation. This method also demonstrated sensitivity, specificity, and positive and negative predictive values of 87.8%, 85.7%, 87.5%, and 86%, respectively. ZAP70 expression was significantly associated with OS (P = 0.0021) and TFS (P &amp;lt;0.0001). ZAP70+ patients had significantly shorter median TFS (24 months) than ZAP70\u2212 patients (157 months) (P &amp;lt;0.0001). Moreover, qPCR-measured ZAP70 expression has greater prognostic power than IGHV mutational status and the other prognostic markers tested.<\/jats:p>\n               <jats:p>Conclusions: ZAP70 mRNA quantification via qPCR is a strong surrogate marker of IGHV mutational status and a powerful prognostic factor.<\/jats:p>","DOI":"10.1373\/clinchem.2007.089326","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T20:39:53Z","timestamp":1187296793000},"page":"1757-1766","source":"Crossref","is-referenced-by-count":29,"title":["Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia"],"prefix":"10.1093","volume":"53","author":[{"given":"Basile","family":"Stamatopoulos","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haibe-Kains","sequence":"first","affiliation":[{"name":"Functional Genomics and Translational Research Unit, Faculty of Medicine, Institut Jules Bordet, Universite\u0301 Libre de Bruxelles (ULB), Brussels, Belgium"},{"name":"Machine Learning Group, Faculty of Sciences, Universite\u0301 Libre de Bruxelles (ULB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hughes","family":"Duvillier","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Massy","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Martiat","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lagneaux","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"2020022802461562000_R1","unstructured":"Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol1998;25:42-59."},{"key":"2020022802461562000_R2","doi-asserted-by":"crossref","unstructured":"Hamblin T. Chronic lymphocytic leukaemia: one disease or two?. Ann Hematol2002;81:299-303.","DOI":"10.1007\/s00277-002-0476-1"},{"key":"2020022802461562000_R3","doi-asserted-by":"crossref","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood1975;46:219-234.","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"2020022802461562000_R4","doi-asserted-by":"crossref","unstructured":"Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198-206.","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"2020022802461562000_R5","doi-asserted-by":"crossref","unstructured":"Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program2003;:153-175.","DOI":"10.1182\/asheducation-2003.1.153"},{"key":"2020022802461562000_R6","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood2004;103:1202-1210.","DOI":"10.1182\/blood-2003-07-2281"},{"key":"2020022802461562000_R7","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:1848-1854.","DOI":"10.1182\/blood.V94.6.1848"},{"key":"2020022802461562000_R8","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:1840-1847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2020022802461562000_R9","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med2001;194:1639-1647.","DOI":"10.1084\/jem.194.11.1639"},{"key":"2020022802461562000_R10","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med2001;194:1625-1638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020022802461562000_R11","unstructured":"van\u2019t Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica2006;91:56-63."},{"key":"2020022802461562000_R12","doi-asserted-by":"crossref","unstructured":"Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia2005;19:1216-1223.","DOI":"10.1038\/sj.leu.2403748"},{"key":"2020022802461562000_R13","doi-asserted-by":"crossref","unstructured":"Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood2003;101:4944-4951.","DOI":"10.1182\/blood-2002-10-3306"},{"key":"2020022802461562000_R14","doi-asserted-by":"crossref","unstructured":"Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro C, Remo A, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia2007;21:102-109.","DOI":"10.1038\/sj.leu.2404458"},{"key":"2020022802461562000_R15","doi-asserted-by":"crossref","unstructured":"Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood2006;108:853-861.","DOI":"10.1182\/blood-2005-12-4986"},{"key":"2020022802461562000_R16","doi-asserted-by":"crossref","unstructured":"Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:1764-1775.","DOI":"10.1056\/NEJMoa023143"},{"key":"2020022802461562000_R17","doi-asserted-by":"crossref","unstructured":"Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia2003;17:2426-2434.","DOI":"10.1038\/sj.leu.2403147"},{"key":"2020022802461562000_R18","doi-asserted-by":"crossref","unstructured":"Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet2004;363:105-111.","DOI":"10.1016\/S0140-6736(03)15260-9"},{"key":"2020022802461562000_R19","doi-asserted-by":"crossref","unstructured":"Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893-901.","DOI":"10.1056\/NEJMoa040857"},{"key":"2020022802461562000_R20","doi-asserted-by":"crossref","unstructured":"Vener C, Gianelli U, Cortelezzi A, Fracchiolla NS, Somalvico F, Savi F, et al. ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. Leuk Lymphoma2006;47:245-251.","DOI":"10.1080\/10428190500272846"},{"key":"2020022802461562000_R21","doi-asserted-by":"crossref","unstructured":"Chen YH, Peterson LC, Dittmann D, Evens A, Rosen S, Khoong A, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to lgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol2007;127:182-191.","DOI":"10.1309\/230199FLE32ATUB0"},{"key":"2020022802461562000_R22","doi-asserted-by":"crossref","unstructured":"Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol2005;27:258-266.","DOI":"10.1111\/j.1365-2257.2005.00703.x"},{"key":"2020022802461562000_R23","doi-asserted-by":"crossref","unstructured":"Catherwood MA, Matthews C, Niblock R, Dobbin E, Morris TC, Alexander HD. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol2006;76:294-298.","DOI":"10.1111\/j.1600-0609.2005.00619.x"},{"key":"2020022802461562000_R24","doi-asserted-by":"crossref","unstructured":"Van Bockstaele F, Janssens A, Piette A, Callewaert F, Pede V, Offner F, et al. Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status. Cytometry B Clin Cytom2006;70:302-308.","DOI":"10.1002\/cyto.b.20122"},{"key":"2020022802461562000_R25","doi-asserted-by":"crossref","unstructured":"Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem1987;162:156-159.","DOI":"10.1016\/0003-2697(87)90021-2"},{"key":"2020022802461562000_R26","doi-asserted-by":"crossref","unstructured":"Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol2005;23:3780-3792.","DOI":"10.1200\/JCO.2005.02.568"},{"key":"2020022802461562000_R27","doi-asserted-by":"crossref","unstructured":"Mertens D, Wolf S, Schroeter P, Schaffner C, Dohner H, Stilgenbauer S, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood2002;99:4116-4121.","DOI":"10.1182\/blood.V99.11.4116"},{"key":"2020022802461562000_R28","doi-asserted-by":"crossref","unstructured":"Li AH, Rosenquist R, Forestier E, Holmberg D, Lindh J, Lofvenberg E, et al. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol1999;63:211-218.","DOI":"10.1111\/j.1600-0609.1999.tb01880.x"},{"key":"2020022802461562000_R29","doi-asserted-by":"crossref","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics2000;56:337-344.","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"2020022802461562000_R30","doi-asserted-by":"crossref","unstructured":"Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology1983;148:839-843.","DOI":"10.1148\/radiology.148.3.6878708"},{"key":"2020022802461562000_R31","doi-asserted-by":"crossref","unstructured":"Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM, et al. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T\/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom2006;70:284-292.","DOI":"10.1002\/cyto.b.20127"},{"key":"2020022802461562000_R32","doi-asserted-by":"crossref","unstructured":"Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B, et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem2007;53:204-212.","DOI":"10.1373\/clinchem.2006.076331"},{"key":"2020022802461562000_R33","doi-asserted-by":"crossref","unstructured":"Boonstra JG, van Lom K, Langerak AW, Graveland WJ, Valk PJ, Kraan J, et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. Cytometry B Clin Cytom2006;70:136-141.","DOI":"10.1002\/cyto.b.20106"},{"key":"2020022802461562000_R34","doi-asserted-by":"crossref","unstructured":"Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, et al. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom2006;70:270-275.","DOI":"10.1002\/cyto.b.20134"},{"key":"2020022802461562000_R35","doi-asserted-by":"crossref","unstructured":"Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood2002;100:1410-1416.","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"2020022802461562000_R36","unstructured":"Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, Beneitez D, Alonso E, Romagosa V, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica2002;87:1021-1027."},{"key":"2020022802461562000_R37","unstructured":"Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica2005;90:391-399."},{"key":"2020022802461562000_R38","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood2002;99:1023-1029.","DOI":"10.1182\/blood.V99.3.1023"},{"key":"2020022802461562000_R39","doi-asserted-by":"crossref","unstructured":"Patten P, Buggins A, Richards J, Wotherspoon A, Hamblin TJ, Mufti G, et al. CD38 expression in B-CLL is dynamic and changes due to contact with activating stimuli found within the leukaemic microenvironment [Abstract]. Annual Meeting of the American Society of Hematology, 2006 Orlando, FL. http:\/\/health.groups.yahoo.com\/group\/CLLResearch\/message\/8776 (accessed May 2007)..","DOI":"10.1182\/blood.V108.11.2798.2798"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/10\/1757\/32690482\/clinchem1757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/10\/1757\/32690482\/clinchem1757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T02:48:21Z","timestamp":1582858101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/53\/10\/1757\/5627291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2007,10,1]]},"published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2007.089326","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,10,1]]},"published":{"date-parts":[[2007,10,1]]}}}